Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability

被引:0
作者
Zhaomeng Wang [1 ]
Mengchi Sun [1 ]
Tian Liu [1 ]
Zisen Gao [2 ]
Qing Ye [1 ]
Xiao Tan [1 ]
Yanxian Hou [1 ]
Jin Sun [1 ]
Dun Wang [2 ]
Zhonggui He [1 ]
机构
[1] Wuya College of Innovation, Shenyang Pharmaceutical University
[2] Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University
关键词
Co-amorphous solid dispersion; Lacidipine; Spironolactone; Stability; Molecular dynamic(MD); simulations;
D O I
暂无
中图分类号
R943 [制剂学];
学科分类号
100602 ; 100702 ;
摘要
Co-amorphous solid dispersion(C-ASD) systems have attracted great attention to improve the solubility of poorly soluble drugs, but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge challenge. Herein, C-ASD system of two clinical combined used drugs(lacidipine(LCDP) and spironolactone(SPL)) as stabilizers to each other,was prepared by solvent evaporation method. The effects of variation in molar ratio of LCDP and SPL(3:1, 1:1, 1:3, 1:6, and 1:9) on the drug release characteristics were explored. Polarized light microscopy(PLM), powder X-ray diffraction(PXRD), differential scanning calorimetry(DSC) and thermogravimetric analysis(TGA) were employed to evaluate the solid states. Prepared C-ASDs were further studied for their stability under the high humidity(RH 92.5%).Further analysis of C-ASDs via Fourier-transform infrared spectroscopy(FTIR) and Raman spectroscopy confirmed that hydrogen bond interactions between the two drugs played a significant role in maintaining the stability of the C-ASDs systems. Moreover, molecular dynamic(MD) simulations provided a clear insight into the stability mechanism at the molecular level. This study demonstrated the novel drug-drug C-ASDs systems is a promising formulation strategy for improved dissolution rate and enhanced physical stability of poorly soluble drugs.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 16 条
[1]  
Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs[J]. Bin Yang,Chunnuan Wu,Bin Ji,Mingrui Wu,Zhonggui He,Lei Shang,Jin Sun.Asian Journal of Pharmaceutical Sciences. 2017(01)
[2]  
Coamorphous Active Pharmaceutical Ingredient–Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability[J] . Ann Newman,Susan M. Reutzel-Edens,George Zografi.Journal of Pharmaceutical Sciences . 2018 (1)
[3]  
Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance[J] . Huijun Chen,Yipshu Pui,Chengyu Liu,Zhen Chen,Ching-Chiang Su,Michael Hageman,Munir Hussain,Roy Haskell,Kevin Stefanski,Kimberly Foster,Olafur Gudmundsson,Feng Qian.Journal of Pharmaceutical Sciences . 2018 (1)
[4]  
Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile[J] . Sakib M. Moinuddin,Sida Ruan,Yuting Huang,Qin Gao,Qin Shi,Baochang Cai,Ting Cai.International Journal of Pharmaceutics . 2017 (1)
[5]  
Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways[J] . Khadijah Edueng,Denny Mahlin,Per Larsson,Christel A.S. Bergstr?m.Journal of Controlled Release . 2017
[6]  
Solid state characterization of azelnidipine–oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs[J] . Yahui Pan,Wenzhe Pang,Jie Lv,Jing Wang,Caiqin Yang,Wei Guo.Journal of Pharmaceutical and Biomedical Analysis . 2017
[7]  
Influence of variation in molar ratio on co-amorphous drug-amino acid systems[J] . Katrine Tarp Jensen,Flemming Hofmann Larsen,Korbinian L?bmann,Thomas Rades,Holger Grohganz.European Journal of Pharmaceutics and Biopharmace . 2016
[8]  
Solvent-shift strategy to identify suitable polymers to inhibit humidity-induced solid-state crystallization of lacidipine amorphous solid dispersions[J] . Mengchi Sun,Chunnuan Wu,Qiang Fu,Donghua Di,Xiao Kuang,Chao Wang,Zhonggui He,Jian Wang,Jin Sun.International Journal of Pharmaceutics . 2016
[9]  
Pharmaceutical excipients — quality, regulatory and biopharmaceutical considerations[J] . David P. Elder,Martin Kuentz,René Holm.European Journal of Pharmaceutical Sciences . 2015
[10]  
Recent advances in co-amorphous drug formulations[J] . Swapnil Jayant Dengale,Holger Grohganz,Thomas Rades,Korbinian L?bmann.Advanced Drug Delivery Reviews . 2015